Clinical Trial Update: BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial of BMS-275291 in hormone-resistant prostate cancer has completed. The study enrolled men with advanced disease, including those with bone metastas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• BMS-275291

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Prostate, Bone Metastases | Phase 2 | Status: COMPLETED